Edition:
United States

AbbVie Inc (ABBV.N)

ABBV.N on New York Stock Exchange

93.17USD
23 Apr 2018
Change (% chg)

$0.57 (+0.62%)
Prev Close
$92.60
Open
$92.93
Day's High
$93.79
Day's Low
$92.73
Volume
1,057,687
Avg. Vol
1,696,438
52-wk High
$125.84
52-wk Low
$64.27

Select another date:

Tue, Apr 10 2018

FDA needs more time to review AbbVie, Neurocrine's uterine pain drug

AbbVie Inc and Neurocrine Biosciences Inc said on Tuesday the U.S. Food and Drug Administration notified the companies that it requires more time to review the marketing application for their uterine pain drug.

UPDATE 2-FDA needs more time to review AbbVie, Neurocrine's uterine pain drug

April 10 AbbVie Inc and Neurocrine Biosciences Inc said on Tuesday the U.S. Food and Drug Administration notified the companies that it requires more time to review the marketing application for their uterine pain drug.

FDA needs more time to review AbbVie, Neurocrine's uterine pain drug

AbbVie Inc and Neurocrine Biosciences Inc said on Tuesday the U.S. Food and Drug Administration notified the companies that it requires more time to review the marketing application for their uterine pain drug.

CORRECTED-UPDATE 1-FDA needs more time to review AbbVie, Neurocrine's uterine pain drug

April 10 AbbVie Inc and Neurocrine Biosciences Inc said on Tuesday the U.S. Food and Drug Administration notified the companies that it requires more time to review the marketing application for their uterine pain drug.

CORRECTED-FDA extends review for AbbVie, Neurocrine's uterine pain drug

April 10 AbbVie Inc and Neurocrine Biosciences Inc said on Tuesday the U.S. Food and Drug Administration notified the companies that it requires more time to review the marketing application for their uterine pain drug.

BRIEF-Abbvie And Neurocrine Biosciences Announce PDUFA Target Date Of Q3 2018 For Elagolix In Endometriosis Associated Pain

April 10 Abbvie And Neurocrine Biosciences Announce Pdufa Target Date Of Q3 2018 For Elagolix In Endometriosis :

BRIEF-AbbVie Says Upadacitinib Met All Primary And Ranked Secondary Endpoints In Phase 3 Study In Rheumatoid Arthritis

* UPADACITINIB MEETS ALL PRIMARY AND RANKED SECONDARY ENDPOINTS INCLUDING SUPERIORITY VERSUS ADALIMUMAB IN PHASE 3 STUDY IN RHEUMATOID ARTHRITIS

AbbVie, Samsung Bioepis in deal; Humira biosimilar U.S. release in 2023

AbbVie Inc on Thursday said it signed a deal with Samsung Bioepis and its joint venture partner Biogen Inc that would fend off U.S. competition of their biosimilar version to blockbuster drug Humira until 2023.

UPDATE 2-AbbVie, Samsung Bioepis in deal; Humira biosimilar U.S. release in 2023

April 5 AbbVie Inc on Thursday said it signed a deal with Samsung Bioepis and its joint venture partner Biogen Inc that would fend off U.S. competition of their biosimilar version to blockbuster drug Humira until 2023.

AbbVie in deal with Biogen to delay Humira biosimilar U.S. launch to 2023

April 5 AbbVie Inc on Thursday said it signed a deal with Biogen Inc and its joint venture partner Samsung Bioepis that would fend off U.S. competition of their rival version to blockbuster drug Humira until 2023.

Select another date: